hotspot -WSS

hotspot

author：Wikipedia 2025-09-03 03:25:28 - browse：87

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Where are patients getting their prescriptions for GLP

leisure time

hotspot

WSS

How Long Island became the ‘eugenics capital of the world’

GOP presidential candidates start declaring their loyalty

GOP presidential candidates start declaring their loyalty

Winners, losers from Medicare’s list of drugs subject to price talks

As pharma fights Medicare drug negotiation, hospitals, docs silent

Kim Kardashian sparks debate on benefits of full

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Medicare details structure of new drug price negotiation program

Complete sequence of Y chromosome published for first time

Medicare proposal to cover medical devices draws a mixed reaction

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

How to save PrEP access — and even expand it

CDC overhauls leadership of center that led response to Covid

Anesthesiologist group: stop taking Ozempic before surgery

Where are patients getting their prescriptions for GLP

BioMarin wins approval for gene therapy to treat hemophilia A

Drug firms test therapies to halt Alzheimer’s before symptoms arise

knowledge

An innovative path out of biotech’s “valley of death”

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

How to make AI work for medicine

What AAP's gender

Neuroscience startup Neumora files for IPO

Maui funeral service workers on devastation of fires: 'I'm in shock'

leisure time

hotspot

focus

knowledge